Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Molecular Targeted Agents / Immunotherapy /

113 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1434

07/03/2014

Expanded Access of MK-3475 in Metastatic Melanoma Patients with Limited to No Treatment Options

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL12117

02/18/2013

A Multi-Site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (YERVOY?) as First-Line Therapy

Molecular Targeted Agents / Immunotherapy / Biologics

Neuroblastoma (Pediatrics)
Pediatric Solid Tumors

VICCPED12112

01/04/2013

NMTRC003: A Phase II Preventative Trial of DFMO (eflornithine HCI) as a Single Agent in Patients with High Risk Neuroblastoma in Remission

Molecular Targeted Agents / Immunotherapy / Biologics

Hematologic
Leukemia
Multiple Myeloma

VICCBMT12104

02/04/2014

Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD)

Molecular Targeted Agents / Immunotherapy / Biologics

Pediatric Solid Tumors

COGACCL0922

02/20/2013

SCUSF0901 - ACCL0922: A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

PRECOGHEM0901

12/04/2012

Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia
Myelodysplastic Syndrome

VICCBMT1218

09/04/2012

A Randomized, Prospective, Double Blind, Placebo-Controlled, Phase 3 Study of US-ATG-F Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients after Allogeneic Stem Cell Transplantation from Unrelated Donors

Molecular Targeted Agents / Immunotherapy / Biologics

Other Skin

VICCNCPED1210

02/20/2012

Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients with Dystrophic Epidermolysis Bullosa.

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCPED0921

05/01/2009

Expanded Access of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD.

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHN13111

08/27/2014

A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone as Second-Line Therapy in Patients with Stage IIIb/IV Non-Squamous Non-Small-Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO1415

08/27/2014

A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Molecular Targeted Agents / Immunotherapy / Biologics

Sarcoma

VICCSAR1419

08/27/2014

A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1436

08/18/2014

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Prostate

VICCURO1450

08/13/2014

PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1430

08/12/2014

A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM1423

08/08/2014

A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI1405

08/07/2014

A Phase 3, Multicenter, Open-Label, Randomized Study of nab?-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Molecular Targeted Agents / Immunotherapy / Biologics

Colon

VICCGI13104

08/06/2014

A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO1429

08/05/2014

An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO1444

08/05/2014

A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate Efficacy and Safety of Roniciclib in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) Who are Receiving Cisplatin + Etoposide or Carboplatin + Etoposide as First-Line Therapy

Molecular Targeted Agents / Immunotherapy / Biologics

Esophageal
Gastric/Gastroesophageal

VICCGI13114

08/04/2014

A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1435

07/31/2014

First-in-Human Dose-Escalation Study of TEW-7197 Monotherapy in Subjects with Advanced Stage Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Neuro-Oncology

VICCNEU1404

07/30/2014

A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM).

Molecular Targeted Agents / Immunotherapy / Biologics

Ovarian

VICCGYN1439

07/23/2014

A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy

Molecular Targeted Agents / Immunotherapy / Biologics

Pediatric Solid Tumors

VICCPED1395

07/18/2014

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHN1332

07/18/2014

A Phase III, Multicenter, Randomized, Open-Label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients with ALK-Rearranged (ALK-Positive) Advanced Non-Small Cell Lung Cancer Who Have Been Treated Previously with Chemotherapy (Platinum Doublet) and Crizotinib

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

ECOGHEME1412

07/17/2014

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

VICCHN1433

07/16/2014

An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM1371

07/14/2014

A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination with Subcutaneous Low-Dose Cytarabine vs. Placebo + Low-Dose Cytarabine in Patients ≥ 65 Years with Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible For Intensive Remission Induction Therapy

Molecular Targeted Agents / Immunotherapy / Biologics

Colon
Rectal

VICCGI13101

06/24/2014

Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Participants with Previously Untreated Metastatic Colorectal Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast - Female

VICCBRE1393

06/23/2014

A Phase II Randomized, Double-Blind Placebo Controlled, Study of Letrozole with or without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women with Hormone Receptor-Positive HER2-Negative Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Neuro-Oncology

VICCNEU13107

06/13/2014

A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI13100

06/10/2014

A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 Compared to Chemotherapy or to CRS-207 Alone in Adults with Previously-Treated Metastatic Pancreatic Adenocarcinoma

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHN1303

06/06/2014

A Randomized Open-Label Phase II Trial of Pemetrexed and a Platinum (Carboplatin or Cisplatin) with or without Erlotinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations and Acquired Resistance to First-Line EGFR TKIs, Erlotinib or Gefitinib

Molecular Targeted Agents / Immunotherapy / Biologics

Bladder
Colon
Esophageal
Gastric/Gastroesophageal
Neuro-Oncology
Ovarian
Urologic
Uterine

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1387

05/28/2014

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MEHD7945A and Cobimetinib in Patients with Locally Advanced or Metastatic Cancers with Mutant KRAS

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma
Neuro-Oncology

VICCMEL1398

05/23/2014

BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation- Positive Melanoma that has Metastasized to the Brain

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1411

05/22/2014

A Phase 1b Study of LY2835219 in Combination with Endocrine Therapies for Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO1420

05/19/2014

An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

VICCMD13112

05/19/2014

Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1375

05/16/2014

Phase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies BVD-523-01

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1391

04/24/2014

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1390

04/23/2014

A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone-Receptor Positive, HER2-negative, Advanced Breast Cancer who Received no Prior Therapy for Advanced Disease

Molecular Targeted Agents / Immunotherapy / Biologics

Esophageal
Gastric/Gastroesophageal
Lung
Non Small Cell
Pancreatic

VICCPHI1360

04/22/2014

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Breast
Colon
Lung
Ovarian
Pancreatic
Prostate
Rectal

VICCPHI1394

04/17/2014

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM13110

04/11/2014

A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM13105

04/09/2014

A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM13106

04/09/2014

A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least Two Prior Multi-Agent Chemotherapy Regimens in Subjects Who Are Not Candidates for ASCT

Molecular Targeted Agents / Immunotherapy / Biologics

Hematologic

VICCHEM1274

03/31/2014

A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMELP1388

03/24/2014

A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, trametinib, Combined with the CDK4/6 Inhibitor, palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects with Solid Tumors.

Molecular Targeted Agents / Immunotherapy / Biologics

Breast - Female

VICCBREP1363

03/21/2014

A Phase Ib/II, Multicenter, Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Hematologic

VICCPED1354

03/17/2014

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients

Molecular Targeted Agents / Immunotherapy / Biologics

Multiple Myeloma

VICCHEM1377

03/14/2014

A Phase 1 Study of Arry-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHN12106

03/12/2014

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia
Lymphoma
Multiple Myeloma

VICCHEM1392

03/12/2014

A Phase 1, Open-label, Dose-Escalation Study of the Safety of SNX-5422 Mesylate in Subjects with Refractory Hematological Malignancies

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1364

03/07/2014

A Phase Ib, Open-Label Study of Oral BGJ398 in Combination with Oral BYL719 in Adult Patients with Select Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoid Leukemia
Myeloid and Monocytic Leukemia

VICCPED1355

03/05/2014

Multi-Center, Open-Label Ranodomized Study of Single or Double Myleoablative Cord Blood Transplantation With or Without Infusion of Off-the-Shelf Ex Vivo Expanded Cyropreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHN1379

02/21/2014

A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB/IV) (SELECT-1)

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1342

02/11/2014

A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects with Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Bladder

VICCURO1382

02/10/2014

A Combined Phase 1 and Phase 2 Study of Albumin-bound Rapamycin Nanoparticles (nab-rapamycin, ABI-009) in the Treatment of BCG Refractory or Recurrent Nonmuscle Invasive Transitional Cell Bladder Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Bladder

VICCURO1367

01/27/2014

An Integrated Phase II/III Open Label, Randomized, Parallel and Controlled Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients with Non-Muscle Invasive Bladder Carcinoma in Situ Disease ("NMIBCis", Meaning CIS and CIS with Ta and/or T1) and Who Have Failed BCG Therapy and Refused Cystectomy

Molecular Targeted Agents / Immunotherapy / Biologics

Hematologic
Leukemia

VICCHEM1346

01/21/2014

A Phase II, Randomized, Comparative Trial of Standard of Care, with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

ECOGTHNR1216

01/10/2014

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM1336

12/09/2013

A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects with Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy

Molecular Targeted Agents / Immunotherapy / Biologics

Breast
Gastric/Gastroesophageal
Lung
Pancreatic

VICCPHI1359

12/03/2013

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Breast - Female
Breast - Male

ECOGBRES1207

10/31/2013

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHNP1353

10/30/2013

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9291 in Patients with Advanced Non Small Cell Lung Cancer who have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent (AURA)

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1351

10/17/2013

A Phase 2 study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

VICCTHN1340

10/14/2013

A Phase II Study of Carboplatin, Nab-Paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM1323

10/03/2013

A Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1255

09/28/2013

Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1287

09/23/2013

A Phase Ib/II Trial of GDC-0941 (a PI3K inhibitor) in combination with Cisplatin in patients with androgen receptor negative Triple Negative Metastatic Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Thyroid

VICCTHN1318

09/19/2013

A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCPHI1328

09/05/2013

A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination with Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma

Molecular Targeted Agents / Immunotherapy / Biologics

Colon
Rectal

ECOGGIS0820

09/03/2013

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

VICCTHN1257

08/30/2013

A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy followed by Standard Chemoradiation/Afatinib in HPV Negative Locally Advanced Stage III/IVa/IVb HNSCC

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1320

08/16/2013

A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer or Non-Small Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Esophageal
Gastric/Gastroesophageal

VICCGI1306

07/11/2013

Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with Trastuzumab in Patients with HER2 Positive Carinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia
Lymphoma
Pediatric Leukemia
Pediatric Lymphoma

VICCPED1338

06/27/2013

T2009-012 - A Phase I Dose Finding Study of Panobinostat in Children with Refractory Hematologic Malignancies

Molecular Targeted Agents / Immunotherapy / Biologics

Colon
Rectum

VICCPHI1314

06/25/2013

A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14- SN38, Antibody-Drug Conjugate) in Patients with Colorectal Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM1284

06/05/2013

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1304

06/04/2013

A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE12101

04/04/2013

A Phase Ib Trial of BYL719 (an a-Specific PI3K Inhibitor) in Combination with Endocrine Therapy in Post-Menopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Multiple Myeloma

VICCHEM12107

03/31/2013

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBREP12116

03/25/2013

An Open-Label, Phase I/IIa Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Prostate

VICCURO1260

03/19/2013

A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients with Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy

Molecular Targeted Agents / Immunotherapy / Biologics

Esophageal

VICCGI1211

03/08/2013

Phase IB/II Study of Induction Chemotherapy with XELOX, followed by Radiation Therapy, Carboplatin and RAD001 in Patients with Esophageal Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1263

01/08/2013

Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-Surgical Model of Advanced, Operable Melanoma

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1256

12/06/2012

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Vemurafenib (RO5185426) Adjuvant Therapy In Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma At High Risk For Recurrence

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHN1242

10/24/2012

A Phase IB, Multi-Center,Open-Label Study of the MTOR Kinase Inhibitor CC-223 in Combination with Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCPHI1248

10/12/2012

An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

ECOGTHNR0920

09/12/2012

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Neuroblastoma (Pediatrics)
Pediatric Solid Tumors

VICCPED1249

08/06/2012

An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI1173

07/31/2012

A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients with Advanced Pancreatic Carcinoma

Molecular Targeted Agents / Immunotherapy / Biologics

VICCTHN1244

07/25/2012

Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Adrenocortical
Bladder
Breast
Cervical
Colon
Dermatologic
Esophageal
GIST
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Liver
Lung
Multiple Myeloma
Neuroendocrine
Ovarian
Pancreatic
Prostate
Rectal
Sarcoma
Small Cell
Uterine

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

CTSUBRENB-43-M

04/26/2012

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

CTSUNSABPBREB-47-M

04/26/2012

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

ECOGHEME2906

01/20/2012

Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age greater than or equal to 60 Years)

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM1096

10/24/2011

A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Molecular Targeted Agents / Immunotherapy / Biologics

Neuro-Oncology

COGACNS0821

10/08/2011

ACNS0821 - Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

ECOGTHNE5508

06/29/2011

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Premetrexed, or Combination of Bevacizumab and Premtrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

ECOGHEME2408

05/10/2011

A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Follwed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma

Molecular Targeted Agents / Immunotherapy / Biologics

Neuroblastoma (Pediatrics)
Pediatric Lymphoma

COGADVL0912

04/05/2011

PH 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-MET, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

Molecular Targeted Agents / Immunotherapy / Biologics

Neuro-Oncology

VICCRAD1060

02/15/2011

A Phase I Trial of Sorafenib and Stereotactic Radiosurgery for Patients with 1-4 Brain Metastases

Molecular Targeted Agents / Immunotherapy / Biologics

Non Small Cell

ECOGTHO5508-M

02/09/2011

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Molecular Targeted Agents / Immunotherapy / Biologics

Liver

CTSUGIC80802-M

12/07/2010

Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

CTSUTHOC30607-M

02/17/2010

ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

GIST

VICCPHI0958

02/05/2010

A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumors in which the Target Kinases Are Linked to Disease Pathophysiology

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

ECOGHNE1305

03/04/2009

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

ECOGHNE1305-M

02/11/2009

A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Non Small Cell

ECOGTHOE1505-M

07/27/2007

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)

Molecular Targeted Agents / Immunotherapy / Biologics

Benign Hematologic

VICCNCPED10101

12/28/2006

Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-Dose TBI and Fludarabine with or without Campath